Bonus Biogroup Stock Fundamentals
| BONS Stock | ILS 11.00 0.50 4.35% |
Bonus Biogroup fundamentals help investors to digest information that contributes to Bonus Biogroup's financial success or failures. It also enables traders to predict the movement of Bonus Stock. The fundamental analysis module provides a way to measure Bonus Biogroup's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bonus Biogroup stock.
Bonus |
Bonus Biogroup Company Shares Outstanding Analysis
Bonus Biogroup's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Bonus Biogroup Shares Outstanding | 1.17 B |
Most of Bonus Biogroup's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bonus Biogroup is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Bonus Biogroup has 1.17 B of shares currently outstending. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The shares outstanding for all Israel stocks is notably lower than that of the firm.
Bonus Biogroup Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bonus Biogroup's current stock value. Our valuation model uses many indicators to compare Bonus Biogroup value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bonus Biogroup competition to find correlations between indicators driving Bonus Biogroup's intrinsic value. More Info.Bonus Biogroup is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bonus Biogroup by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bonus Biogroup's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bonus Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bonus Biogroup's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bonus Biogroup could also be used in its relative valuation, which is a method of valuing Bonus Biogroup by comparing valuation metrics of similar companies.Bonus Biogroup is currently under evaluation in shares outstanding category among its peers.
Bonus Fundamentals
| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 | |||
| Current Valuation | 169.66 M | |||
| Shares Outstanding | 1.17 B | |||
| Shares Owned By Insiders | 49.72 % | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 3.39 X | |||
| EBITDA | (88.03 M) | |||
| Net Income | (90.08 M) | |||
| Cash And Equivalents | 3.6 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 6.28 M | |||
| Current Ratio | 0.35 X | |||
| Book Value Per Share | 0.12 X | |||
| Cash Flow From Operations | (39.84 M) | |||
| Earnings Per Share | (0.08) X | |||
| Number Of Employees | 13 | |||
| Beta | 1.4 | |||
| Market Capitalization | 223.15 M | |||
| Total Asset | 104.32 M | |||
| Z Score | 21.0 | |||
| Net Asset | 104.32 M |
About Bonus Biogroup Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bonus Biogroup's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bonus Biogroup using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bonus Biogroup based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. Bonus BioGroup Ltd., formerly known as Oceana Advanced Industries Ltd., was founded in 1981 and is based in Haifa, Israel. BONUS BIOGROUP is traded on Tel Aviv Stock Exchange in Israel.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Bonus Stock
Bonus Biogroup financial ratios help investors to determine whether Bonus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bonus with respect to the benefits of owning Bonus Biogroup security.